Prestige Consumer Healthcare Inc. (PBH) intrinsic value & 10-year financials
Prestige Consumer Healthcare Inc. (PBH) has a Graham intrinsic value of $82.65 per share. At $49.92 on Oct 17, 2026, the stock trades 40% below that value. Over the last 10 fiscal years revenue grew 2.4% a year to $1.1B, with an average return on invested capital of 6.5%.
- Graham intrinsic value
- $82.65
- Share price (Oct 17, 2026)
- $49.92
- Price vs Graham value
- 40% below
- Market cap
- $2.4B
- Revenue (FY2026)
- $1.1B
- Revenue growth (10-yr CAGR)
- 2.4%
- ROIC (10-yr avg)
- 6.5%
- Free cash flow (FY2026)
- $246.4M
PBH 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2026 | $1.1B | $190.3M | $3.91 | $246.4M | 28.4% | 8.1% |
| FY2025 | $1.1B | $214.6M | $4.29 | $243.3M | 29.6% | 9.2% |
| FY2024 | $1.1B | $209.3M | $4.17 | $239.4M | 30.4% | 9.5% |
| FY2023 | $1.1B | -$82.3M | -$1.65 | $221.9M | -2.0% | -0.7% |
| FY2022 | $1.1B | $205.4M | $4.04 | $250.3M | 30.4% | 8.8% |
| FY2021 | $943.4M | $164.7M | $3.25 | $213.4M | 31.5% | 8.5% |
| FY2020 | $963.0M | $142.3M | $2.78 | $202.6M | 30.2% | 7.6% |
| FY2019 | $975.8M | -$35.8M | -$0.69 | $178.8M | 6.9% | 2.1% |
| FY2018 | $1.0B | $339.6M | $6.34 | $197.6M | 20.7% | 7.1% |
| FY2017 | $882.1M | $69.4M | $1.30 | $144.8M | 23.3% | 4.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Prestige Consumer Healthcare Inc. has demonstrated mature, steady growth, with revenue compounding at 2.4% annually over the past decade.
Prestige Consumer Healthcare Inc. has historically struggled to out-earn its cost of capital, averaging just 6.4% ROIC.
Prestige Consumer Healthcare Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Prestige Consumer Healthcare Inc. is modeled at 8.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $82.65 per share.